Wegovy HD (semaglutide 7.2mg)
Obesity
ApprovedRecently approved in US
Key Facts
About Novo Nordisk
Novo Nordisk has established itself as the dominant player in the diabetes and obesity treatment markets through its innovative GLP-1 receptor agonist portfolio. The company's purpose is to drive change to defeat diabetes and other serious chronic diseases, with a robust pipeline spanning multiple therapeutic areas including cardiovascular disease, rare blood disorders, and metabolic diseases. Recent regulatory approvals, including Wegovy HD (semaglutide 7.2 mg) providing 20.7% mean weight loss, demonstrate continued innovation and market expansion. The company maintains a strong financial position and is expanding global access to its treatments through strategic partnerships.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Zepbound) | Eli Lilly | Approved |
| APJ Program | BioAge Labs | Preclinical |
| Amylin analogue (subcutaneous) | Novo Nordisk | Phase 1 |
| GLP1-GIP-Amylin tri-agonist | Novo Nordisk | Phase 2 |
| VK2735 (subcutaneous) | Viking Therapeutics | Phase 3 |
| VK2735 (oral) | Viking Therapeutics | Phase 1/2 |
| GSBR-1290 | Structure Therapeutics | Phase 2 |
| LTSE-2578 | Structure Therapeutics | Preclinical |
| Survodutide (BI 456906) | Zealand Pharma | Phase 3 |
| ZP8396 | Zealand Pharma | Preclinical/Phase 1 |
| Pemvidutide (ALT-801) | Altimmune | Phase 2 |
| PL7737 | Palatin Technologies | Preclinical |